Aspyrian and Goodwin team to 'shed light' on ADC candidate

By Dan Stanton

- Last updated on GMT

Related tags Immune system

New ADC platform uses infrared light to activate payload
New ADC platform uses infrared light to activate payload
Aspyrian Therapeutics has teamed up with Goodwin Biotech to make antibody-drug conjugates (ADCs) with a technology platform that uses near‐infrared (NIR) light to activate the cytotoxin.

San Diego‐based start‐up Aspyrian has selected Goodwin to manufacture its ADC candidate using the near‐infrared Photoimmunotherapy (PIT) platform exclusively licensed from the National Cancer Institute.

Whilst conventional ADC platforms have been hindered by dose-limiting adverse effects to the payload, the PIT technology avoids this by ensuring the cytotoxin remains inert until the ADC is in the tumour itself, according to Aspyrian, when it is then activated by near‐infrared (NIR) light.

PIT is based, therefore, on the antibody itself which binds to cell-surface antigens, the NIR IR700DX dye which is conjugated to the antibody via a linker, and the light which commences the cell killing.

The firm says the selective binding and localised NIR activation is highly efficient in destroying diseased cells, whilst sparing to nearby healthy tissue and hopes to take its first product – for the treatment of neck and head cancer – into Phase I trials by the end of the year.

The deal with Goodwin – of which financial details were not divulged – will see Aspyrian use the CMO for the technology transfer, development, scale-up and cGMP manufacturing of the ADC.

“This important project is a testament to our experience and expertise in bioconjugation that has been developed and refined over more than a decade,”​ said Goodwin COO SooYoung Lee.

In May 2013, Goodwin teamed up with fellow US contract manufacturer Coldstream Laboratories to begin offering clients ADC capabilities, with the former providing pre-formulation development and the latter clinical and commercial.

Speaking with sister publication last year, Goodwin’s Director of Marketing David Cunningham said “the economics and efficacy of ADCs have always been compelling,”​ with the firm seeing a “very high demand within the biopharmaceutical sector from small and virtual companies to large and established multinationals.”

Related news

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers